The interplay between the tumor microenvironment and tumor-derived small extracellular vesicles in cancer development and therapeutic response

References

• Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett. 2015;368(1):7–23. doi: 10.1016/j.canlet.2015.07.039.
   PubMed Web of Science ®Google Scholar
• Zhou J, Li Q, Cao Y. Spatiotemporal heterogeneity across metastases and organ-specific response informs drug efficacy and patient survival in colorectal cancer. Cancer Res. 2021;81(9):2522–2533. doi: 10.1158/0008-5472.CAN-20-3665.
   PubMed Web of Science ®Google Scholar
• Song M, Liu Q, Sun W, Zhang H. Crosstalk between thyroid carcinoma and tumor-correlated immune cells in the tumor microenvironment. Cancers Basel. 2023;15(10):2863. doi: 10.3390/cancers15102863.
   PubMed Web of Science ®Google Scholar
• Michiels C, Tellier C, Feron O. Cycling hypoxia: a key feature of the tumor microenvironment. Biochim Biophys Acta. 2016;1866(1):76–86. doi: 10.1016/j.bbcan.2016.06.004.
   PubMed Web of Science ®Google Scholar
• Boedtkjer E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer. Annu Rev Physiol. 2020;82(1):103–126. doi: 10.1146/annurev-physiol-021119-034627.
   PubMed Web of Science ®Google Scholar
• Reinfeld BI, Madden MZ, Wolf MM, Chytil A, Bader JE, Patterson AR, Sugiura A, Cohen AS, Ali A, Do BT, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 2021;593(7858):282–288. doi: 10.1038/s41586-021-03442-1.
   PubMed Web of Science ®Google Scholar
• Gurusamy D, Clever D, Eil R, Restifo NP. Novel “elements” of immune suppression within the tumor microenvironment. Cancer Immunol Res. 2017;5(6):426–433. doi: 10.1158/2326-6066.CIR-17-0117.
   PubMed Web of Science ®Google Scholar
• Welsh JA, Goberdhan DCI, O’Driscoll L, Buzas EI, Blenkiron C, Bussolati B, Cai H, Di Vizio D, Driedonks TAP, Erdbrügger U, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. doi: 10.1002/jev2.12404.
   PubMed Web of Science ®Google Scholar
• Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, Sabet S, Khoshbakht MA, Hashemi M, Hushmandi K, et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol. 2022;15(1):83. doi: 10.1186/s13045-022-01305-4.
   PubMed Web of Science ®Google Scholar
• Wang X, Huang J, Chen W, Li G, Li Z, Lei J. The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer. Experiment Molecul Med. 2022;54(9):1390–1400. doi: 10.1038/s12276-022-00855-4.
   PubMed Web of Science ®Google Scholar
• Tan S, Yang Y, Yang W, Han Y, Huang L, Yang R, Hu Z, Tao Y, Liu L, Li Y, et al. Exosomal cargos-mediated metabolic reprogramming in tumor microenvironment. J Exp Clin Cancer Res. 2023;42(1):59. doi: 10.1186/s13046-023-02634-z.
   PubMed Web of Science ®Google Scholar
• Logozzi M, Mizzoni D, Angelini DF, Di Raimo R, Falchi M, Battistini L, Fais S. Microenvironmental pH and exosome levels interplay in human cancer cell lines of different histotypes. Cancers Basel. 2018;10(10):370. doi: 10.3390/cancers10100370.
   PubMed Web of Science ®Google Scholar
• Suetsugu A, Honma K, Saji S, Moriwaki H, Ochiya T, Hoffman RM. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv Drug Deliv Rev. 2013;65(3):383–390. doi: 10.1016/j.addr.2012.08.007.
   PubMed Web of Science ®Google Scholar
• Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. doi: 10.1126/science.aau6977.
   PubMed Web of Science ®Google Scholar
• Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–383. doi: 10.1083/jcb.201211138.
   PubMed Web of Science ®Google Scholar
• Urbanelli L, Magini A, Buratta S, Brozzi A, Sagini K, Polchi A, Tancini B, Emiliani C. Signaling pathways in exosomes biogenesis, secretion and fate. Genes. 2013;4(2):152–170. doi: 10.3390/genes4020152.
   PubMed Web of Science ®Google Scholar
• Rastogi S, Sharma V, Bharti PS, Rani K, Modi GP, Nikolajeff F, Kumar S. The evolving landscape of exosomes in neurodegenerative diseases: exosomes characteristics and a promising role in early diagnosis. Int J Mol Sci. 2021;22(1):440. doi: 10.3390/ijms22010440.
   PubMed Web of Science ®Google Scholar
• Radulovic M, Stenmark H. ESCRTs in membrane sealing. Biochem Soc Trans. 2018;46(4):773–778. doi: 10.1042/BST20170435.
   PubMedGoogle Scholar
• Kenific CM, Zhang H, Lyden D. An exosome pathway without an ESCRT. Cell Res. 2021;31(2):105–106. doi: 10.1038/s41422-020-00418-0.
   PubMed Web of Science ®Google Scholar
• Cocucci E, Meldolesi J. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. Trends Cell Biol. 2015;25(6):364–372. doi: 10.1016/j.tcb.2015.01.004.
   PubMed Web of Science ®Google Scholar
• Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30(1):255–289. doi: 10.1146/annurev-cellbio-101512-122326.
   PubMed Web of Science ®Google Scholar
• Antonyak MA, Wilson KF, Cerione RA. R(h)oads to microvesicles. Small GTPases. 2012;3(4):219–224. doi: 10.4161/sgtp.20755.
   PubMedGoogle Scholar
• Muralidharan-Chari V, Clancy J, Plou C, Romao M, Chavrier P, Raposo G, D’Souza-Schorey C. ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol. 2009;19(22):1875–1885. doi: 10.1016/j.cub.2009.09.059.
   PubMed Web of Science ®Google Scholar
• Sedgwick AE, Clancy JW, Olivia Balmert M, D’Souza-Schorey C. Extracellular microvesicles and invadopodia mediate non-overlapping modes of tumor cell invasion. Sci Rep. 2015;5(1):14748. doi: 10.1038/srep14748.
   PubMedGoogle Scholar
• Palmisano G, Jensen SS, Le Bihan MC, Lainé J, McGuire JN, Pociot F, Larsen MR. Characterization of membrane-shed microvesicles from cytokine-stimulated β-cells using proteomics strategies. Molecul Cellul Proteomic: MCP. 2012;11(8):230–243. doi: 10.1074/mcp.M111.012732.
   PubMed Web of Science ®Google Scholar
• Tricarico C, Clancy J, D’Souza-Schorey C. Biology and biogenesis of shed microvesicles. Small GTPases. 2017;8(4):220–232. doi: 10.1080/21541248.2016.1215283.
   PubMedGoogle Scholar
• Li S, Man Q, Gao X, Lin H, Wang J, Su F-C, Wang H-Q, Bu L-L, Liu B, Chen G, et al. Tissue‐derived extracellular vesicles in cancers and non‐cancer diseases: present and future. J Extracellular Vesicle. 2021;10(14):e12175. doi: 10.1002/jev2.12175.
   PubMed Web of Science ®Google Scholar
• Bai S, Wang Z, Wang M, Li J, Wei Y, Xu R, Du J. Tumor-derived exosomes modulate primary site tumor metastasis. Front Cell Dev Biol. 2022;10:752818. doi: 10.3389/fcell.2022.752818.
   PubMed Web of Science ®Google Scholar
• Han QF, Li WJ, Hu KS, Gao J, Zhai W-L, Yang J-H, Zhang S-J. Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. Mol Cancer. 2022;21(1):207. doi: 10.1186/s12943-022-01671-0.
   PubMed Web of Science ®Google Scholar
• De Toro J, Herschlik L, Waldner C, Mongini C. Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Front Immunol. 2015;6:203. doi: 10.3389/fimmu.2015.00203.
   PubMed Web of Science ®Google Scholar
• Kosaka N. Decoding the secret of cancer by means of extracellular vesicles. JCM. 2016;5(2):22. doi: 10.3390/jcm5020022.
   Google Scholar
• Ciardiello C, Cavallini L, Spinelli C, Yang J, Reis-Sobreiro M, de Candia P, Minciacchi V, Di Vizio D. Focus on extracellular vesicles: new frontiers of cell-to-cell communication in cancer. Int J Mol Sci. 2016;17(2):175. doi: 10.3390/ijms17020175.
   PubMed Web of Science ®Google Scholar
• Falasca M, Kim M, Casari I. Pancreatic cancer: current research and future directions. Biochim Biophys Acta. 2016;1865(2):123–132. doi: 10.1016/j.bbcan.2016.01.001.
   PubMed Web of Science ®Google Scholar
• Shao H, Chung J, Issadore D. 2016. Diagnostic technologies for circulating tumour cells and exosomes. Biosci Rep. 36(1):e00292. doi: 10.1042/BSR20150180.
   Google Scholar
• Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014;14(3):195–208. doi: 10.1038/nri3622.
   PubMed Web of Science ®Google Scholar
• King HW, Michael MZ, Gleadle JM. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer. 2012;12(1):421. doi: 10.1186/1471-2407-12-421.
   PubMed Web of Science ®Google Scholar
• Yu X, Harris SL, Levine AJ. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 2006;66(9):4795–4801. doi: 10.1158/0008-5472.CAN-05-4579.
   PubMed Web of Science ®Google Scholar
• Thompson CA, Purushothaman A, Ramani VC, Vlodavsky I, Sanderson RD. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem. 2013;288(14):10093–10099. doi: 10.1074/jbc.C112.444562.
   PubMed Web of Science ®Google Scholar
• Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, Moita CF, Schauer K, Hume AN, Freitas RP, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010;12(1):19–30. doi: 10.1038/ncb2000.
   PubMed Web of Science ®Google Scholar
• Bobrie A, Théry C. Unraveling the physiological functions of exosome secretion by tumors. Oncoimmunol. 2013;2(1):e22565. doi: 10.4161/onci.22565.
   PubMed Web of Science ®Google Scholar
• Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar CM, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18(6):883–891. doi: 10.1038/nm.2753.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Exosomes carrying immunoinhibitory proteins and their role in cancer. Clin Exp Immunol. 2017;189(3):259–267. doi: 10.1111/cei.12974.
   PubMed Web of Science ®Google Scholar
• Wu B, Liu DA, Guan L, Myint PK, Chin L, Dang H, Xu Y, Ren J, Li T, Yu Z, et al. Stiff matrix induces exosome secretion to promote tumour growth. Nat Cell Biol. 2023;25(3):415–424. doi: 10.1038/s41556-023-01092-1.
   PubMed Web of Science ®Google Scholar
• Luo C, Xin H, Zhou Z, Hu Z, Sun R, Yao N, Sun Q, Borjigin U, Wu X, Fan J, et al. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression. Hepatology. 2022;76(4):982–999. doi: 10.1002/hep.32387.
   PubMed Web of Science ®Google Scholar
• Bister N, Pistono C, Huremagic B, Jolkkonen J, Giugno R, Malm T. Hypoxia and extracellular vesicles: a review on methods, vesicular cargo and functions. J Extracell Vesicles. 2020;10(1):e12002. doi: 10.1002/jev2.12002.
   PubMed Web of Science ®Google Scholar
• Kumar A, Deep G. Hypoxia in tumor microenvironment regulates exosome biogenesis: molecular mechanisms and translational opportunities. Cancer Lett. 2020;479:23–30. doi: 10.1016/j.canlet.2020.03.017.
   PubMed Web of Science ®Google Scholar
• Jung KO, Jo H, Yu JH, Gambhir SS, Pratx G. Development and MPI tracking of novel hypoxia-targeted theranostic exosomes. Biomater. 2018;177:139–148. doi: 10.1016/j.biomaterials.2018.05.048.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yin K, Tian J, Xia X, Ma J, Tang X, Xu H, Wang S. Granulocytic myeloid-derived suppressor cells promote the stemness of colorectal cancer cells through Exosomal S100A9. Adv Sci (Weinh). 2019;6(18):1901278. doi: 10.1002/advs.201901278.
   PubMedGoogle Scholar
• Ren R, Sun H, Ma C, Liu J, Wang H. Colon cancer cells secrete exosomes to promote self-proliferation by shortening mitosis duration and activation of STAT3 in a hypoxic environment. Cell Biosci. 2019;9(1):62. doi: 10.1186/s13578-019-0325-8.
   PubMed Web of Science ®Google Scholar
• Li J, Yuan H, Xu H, Zhao H, Xiong N. Hypoxic cancer-secreted exosomal miR-182-5p promotes glioblastoma angiogenesis by targeting Kruppel-like factor 2 and 4. Mol Cancer Res. 2020;18(8):1218–1231. doi: 10.1158/1541-7786.MCR-19-0725.
   PubMed Web of Science ®Google Scholar
• Xia X, Wang S, Ni B, Xing S, Cao H, Zhang Z, Yu F, Zhao E, Zhao G. Hypoxic gastric cancer-derived exosomes promote progression and metastasis via MiR-301a-3p/PHD3/HIF-1α positive feedback loop. Oncogene. 2020;39(39):6231–6244. doi: 10.1038/s41388-020-01425-6.
   PubMed Web of Science ®Google Scholar
• Matsuura Y, Wada H, Eguchi H, Gotoh K, Kobayashi S, Kinoshita M, Kubo M, Hayashi K, Iwagami Y, Yamada D, et al. Exosomal miR-155 derived from hepatocellular carcinoma cells under hypoxia promotes angiogenesis in endothelial cells. Dig Dis Sci. 2019;64(3):792–802. doi: 10.1007/s10620-018-5380-1.
   PubMed Web of Science ®Google Scholar
• Patton MC, Zubair H, Khan MA, Singh S, Singh AP. Hypoxia alters the release and size distribution of extracellular vesicles in pancreatic cancer cells to support their adaptive survival. J Cell Biochem. 2020;121(1):828–839. doi: 10.1002/jcb.29328.
   PubMed Web of Science ®Google Scholar
• Ramteke A, Ting H, Agarwal C, Mateen S, Somasagara R, Hussain A, Graner M, Frederick B, Agarwal R, Deep G, et al. Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules. Mol Carcinog. 2015;54(7):554–565. doi: 10.1002/mc.22124.
   PubMed Web of Science ®Google Scholar
• Liu W, Li L, Rong Y, Qian D, Chen J, Zhou Z, Luo Y, Jiang D, Cheng L, Zhao S, et al. Hypoxic mesenchymal stem cell-derived exosomes promote bone fracture healing by the transfer of miR-126. Acta Biomater. 2020;103:196–212. doi: 10.1016/j.actbio.2019.12.020.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhou X, Yao Q, Liu Y, Zhang H, Dong Z. HIF-1-mediated production of exosomes during hypoxia is protective in renal tubular cells. Am J Physiol Renal Physiol. 2017;313(4):F906–F913. doi: 10.1152/ajprenal.00178.2017.
   PubMed Web of Science ®Google Scholar
• Zhu LP, Tian T, Wang JY, He J-N, Chen T, Pan M, Xu L, Zhang H-X, Qiu X-T, Li C-C, et al. Hypoxia-elicited mesenchymal stem cell-derived exosomes facilitates cardiac repair through miR-125b-mediated prevention of cell death in myocardial infarction. Theranostic. 2018;8(22):6163–6177. doi: 10.7150/thno.28021.
   PubMed Web of Science ®Google Scholar
• van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213–228. doi: 10.1038/nrm.2017.125.
   PubMed Web of Science ®Google Scholar
• Villarroya-Beltri C, Baixauli F, Mittelbrunn M, Fernández-Delgado I, Torralba D, Moreno-Gonzalo O, Baldanta S, Enrich C, Guerra S, Sánchez-Madrid F, et al. ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins. Nat Commun. 2016;7(1):13588. doi: 10.1038/ncomms13588.
   PubMedGoogle Scholar
• Zieseniss A. Hypoxia and the modulation of the actin cytoskeleton - emerging interrelations. Hypoxia (Auckl). 2014;2:11–21. doi: 10.2147/HP.S53575.
   PubMedGoogle Scholar
• Cao H, Yu D, Yan X, Wang B, Yu Z, Song Y, Sheng L. Hypoxia destroys the microstructure of microtubules and causes dysfunction of endothelial cells via the PI3K/Stathmin1 pathway. Cell & Bioscience. 2019;9(1):20. doi: 10.1186/s13578-019-0283-1.
   PubMedGoogle Scholar
• Lee HJ, Jung YH, Oh JY, Choi GE, Chae CW, Kim JS, Lim JR, Kim SY, Lee S-J, Seong JK, et al. BICD1 mediates HIF1α nuclear translocation in mesenchymal stem cells during hypoxia adaptation. Cell Death Differ. 2019;26(9):1716–1734. doi: 10.1038/s41418-018-0241-1.
   PubMed Web of Science ®Google Scholar
• He G, Peng X, Wei S, Yang S, Li X, Huang M, Tang S, Jin H, Liu J, Zhang S, et al. Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications. Mol Cancer. 2022;21(1):19. doi: 10.1186/s12943-021-01440-5.
   PubMed Web of Science ®Google Scholar
• Bjørnetrø T, Redalen KR, Meltzer S, Thusyanthan NS, Samiappan R, Jegerschöld C, Handeland KR, Ree AH. An experimental strategy unveiling exosomal microRnas 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer. J Extracell Vesicles. 2019;8(1):1567219. doi: 10.1080/20013078.2019.1567219.
   PubMed Web of Science ®Google Scholar
• Zhang X, Sai B, Wang F, Wang L, Wang Y, Zheng L, Li G, Tang J, Xiang J. Hypoxic BMSC-derived exosomal miRnas promote metastasis of lung cancer cells via STAT3-induced EMT. Mol Cancer. 2019;18(1):40. doi: 10.1186/s12943-019-0959-5.
   PubMed Web of Science ®Google Scholar
• Mo F, Xu Y, Zhang J, Zhu L, Wang C, Chu X, Pan Y, Bai Y, Shao C, Zhang J, et al. Effects of hypoxia and radiation-induced exosomes on migration of lung cancer cells and angiogenesis of umbilical vein endothelial cells. Radiat Res. 2020;194(1):71–80. doi: 10.1667/RR15555.1.
   PubMed Web of Science ®Google Scholar
• Deep G, Jain A, Kumar A, Agarwal C, Kim S, Leevy WM, Agarwal R. Exosomes secreted by prostate cancer cells under hypoxia promote matrix metalloproteinases activity at pre-metastatic niches. Mol Carcinog. 2020;59(3):323–332. doi: 10.1002/mc.23157.
   PubMed Web of Science ®Google Scholar
• Hannafon BN, Gin AL, Xu YF, Bruns M, Calloway CL, Ding WQ. Metastasis-associated protein 1 (MTA1) is transferred by exosomes and contributes to the regulation of hypoxia and estrogen signaling in breast cancer cells. Cell Commun Signal. 2019;17(1):13. doi: 10.1186/s12964-019-0325-7.
   PubMedGoogle Scholar
• Wang W, Han Y, Jo HA, Lee J, Song YS. Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment. J Hematol Oncol. 2020;13(1):67. doi: 10.1186/s13045-020-00893-3.
   PubMed Web of Science ®Google Scholar
• Yu Y, Min Z, Zhihang Z, Linhong M, Tao R, Yan L, Song H. Hypoxia-induced exosomes promote hepatocellular carcinoma proliferation and metastasis via miR-1273f transfer. Experiment Cell Res. 2019;385(1):111649. doi: 10.1016/j.yexcr.2019.111649.
   PubMed Web of Science ®Google Scholar
• Liu Y, Tan J, Ou S, Chen J, Chen L. Adipose-derived exosomes deliver miR-23a/b to regulate tumor growth in hepatocellular cancer by targeting the VHL/HIF axis. J Physiol Biochem. 2019;75(3):391–401. doi: 10.1007/s13105-019-00692-6.
   PubMed Web of Science ®Google Scholar
• Xue M, Chen W, Xiang A, Wang R, Chen H, Pan J, Pang H, An H, Wang X, Hou H, et al. Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1. Mol Cancer. 2017;16(1):143. doi: 10.1186/s12943-017-0714-8.
   PubMed Web of Science ®Google Scholar
• Li L, Cao B, Liang X, Lu S, Luo H, Wang Z, Wang S, Jiang J, Lang J, Zhu G, et al. Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral γδ T cell equilibrium via tumor-derived exosomes. Oncogene. 2019;38(15):2830–2843. doi: 10.1038/s41388-018-0627-z.
   PubMed Web of Science ®Google Scholar
• Wang X, Luo G, Zhang K, Cao J, Huang C, Jiang T, Liu B, Su L, Qiu Z. Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kγ to promote pancreatic cancer metastasis. Cancer Res. 2018;78(16):4586–4598. doi: 10.1158/0008-5472.CAN-17-3841.
   PubMed Web of Science ®Google Scholar
• Chen LQ, Pagel MD. Evaluating pH in the extracellular tumor microenvironment using CEST MRI and other imaging methods. Adv Radiol. 2015;2015:1–25. doi: 10.1155/2015/206405.
   Google Scholar
• Ban JJ, Lee M, Im W, Kim M. Low pH increases the yield of exosome isolation. Biochem Biophys Res Commun. 2015;461(1):76–79. doi: 10.1016/j.bbrc.2015.03.172.
   PubMed Web of Science ®Google Scholar
• Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, Coscia C, Iessi E, Logozzi M, Molinari A, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009;284(49):34211–34222. doi: 10.1074/jbc.M109.041152.
   PubMed Web of Science ®Google Scholar
• Logozzi M, Angelini DF, Iessi E, Mizzoni D, Di Raimo R, Federici C, Lugini L, Borsellino G, Gentilucci A, Pierella F, et al. Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients. Cancer Lett. 2017;403:318–329. doi: 10.1016/j.canlet.2017.06.036.
   PubMed Web of Science ®Google Scholar
• Gong C, Zhang X, Shi M, Li F, Wang S, Wang Y, Wang Y, Wei W, Ma G. Tumor exosomes reprogrammed by low pH are efficient targeting vehicles for smart drug delivery and personalized therapy against their homologous tumor. Adv Sci (Weinh). 2021;8(10):2002787. doi: 10.1002/advs.202002787.
   PubMedGoogle Scholar
• Hisey CL, Dorayappan KDP, Cohn DE, Selvendiran K, Hansford DJ. Microfluidic affinity separation chip for selective capture and release of label-free ovarian cancer exosomes. Lab Chip. 2018;18(20):3144–3153. doi: 10.1039/c8lc00834e.
   PubMed Web of Science ®Google Scholar
• Tian XP, Wang CY, Jin XH, Li M, Wang F-W, Huang W-J, Yun J-P, Xu R-H, Cai Q-Q, Xie D, et al. Acidic microenvironment up-regulates exosomal miR-21 and miR-10b in early-stage hepatocellular carcinoma to promote cancer cell proliferation and metastasis. Theranostic. 2019;9(7):1965–1979. doi: 10.7150/thno.30958.
   PubMed Web of Science ®Google Scholar
• He L, Zhu W, Chen Q, Yuan Y, Wang Y, Wang J, Wu X. Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. Theranostic. 2019;9(26):8206–8220. doi: 10.7150/thno.37455.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Li Y, Pan Y, Lan X, Song F, Sun J, Zhou K, Liu X, Ren X, Wang F, et al. Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat Commun. 2018;9(1):5395. doi: 10.1038/s41467-018-07810-w.
   PubMed Web of Science ®Google Scholar
• Zhou CF, Ma J, Huang L, Yi H-Y, Zhang Y-M, Wu X-G, Yan R-M, Liang L, Zhong M, Yu Y-H, et al. Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene. 2019;38(8):1256–1268. doi: 10.1038/s41388-018-0511-x.
   PubMed Web of Science ®Google Scholar
• Ma Z, Wei K, Yang F, Guo Z, Pan C, He Y, Wang J, Li Z, Chen L, Chen Y, et al. Tumor-derived exosomal miR-3157-3p promotes angiogenesis, vascular permeability and metastasis by targeting TIMP/KLF2 in non-small cell lung cancer. Cell Death Dis. 2021;12(9):840. doi: 10.1038/s41419-021-04037-4.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang L, Zhou X, Luo X, Liu K, Jiang E, Chen Y, Shao Z, Shang Z. OSCC exosomes regulate miR-210-3p targeting EFNA3 to promote oral cancer angiogenesis through the PI3K/AKT pathway. BioMed Res Int. 2020;2020:1–13. doi: 10.1155/2020/2125656.
   Web of Science ®Google Scholar
• Muhsin-Sharafaldine MR, Saunderson SC, Dunn AC, Faed JM, Kleffmann T, McLellan AD. Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles. Oncotarget. 2016;7(35):56279–56294. doi: 10.18632/oncotarget.10783.
   PubMedGoogle Scholar
• Li Y, Chen ZK, Duan X, Zhang H-J, Xiao B-L, Wang K-M, Chen G. Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer. Experiment Molecul Med. 2022;54(9):1379–1389. doi: 10.1038/s12276-022-00856-3.
   PubMed Web of Science ®Google Scholar
• Tang Q, Yang S, He G, Zheng H, Zhang S, Liu J, Wei S, Fan Q, Peng X, Li X, et al. Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy. Cancer Lett. 2022;548:215823. doi: 10.1016/j.canlet.2022.215823.
   PubMed Web of Science ®Google Scholar
• Wolfers J, Lozier A, Raposo G, Regnault A, Théry C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001;7(3):297–303. doi: 10.1038/85438.
   PubMed Web of Science ®Google Scholar
• Li M, Xu H, Qi Y, Pan Z, Li B, Gao Z, Zhao R, Xue H, Li G. Tumor-derived exosomes deliver the tumor suppressor miR-3591-3p to induce M2 macrophage polarization and promote glioma progression. Oncogene. 2022;41(41):4618–4632. doi: 10.1038/s41388-022-02457-w.
   PubMed Web of Science ®Google Scholar
• Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382–386. doi: 10.1038/s41586-018-0392-8.
   PubMed Web of Science ®Google Scholar
• Rezaei R, Baghaei K, Hashemi SM, Zali MR, Ghanbarian H, Amani D. Tumor-derived exosomes enriched by miRNA-124 promote anti-tumor immune response in CT-26 tumor-bearing mice. Front Med. 2021;8:619939. doi: 10.3389/fmed.2021.619939.
   Web of Science ®Google Scholar
• Altieri SL, Khan ANH, Tomasi TB. Exosomes from plasmacytoma cells as a tumor vaccine. J Immunother. 2004;27(4):282–288. doi: 10.1097/00002371-200407000-00004.
   PubMed Web of Science ®Google Scholar
• Cheng L, Wang Y, Huang L. Exosomes from M1-polarized macrophages potentiate the cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node. Mol Ther. 2017;25(7):1665–1675. doi: 10.1016/j.ymthe.2017.02.007.
   PubMed Web of Science ®Google Scholar
• Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30(1):36–50. doi: 10.1016/j.cmet.2019.06.001.
   PubMed Web of Science ®Google Scholar
• Xu Z, Chen Y, Ma L, Chen Y, Liu J, Guo Y, Yu T, Zhang L, Zhu L, Shu Y, et al. Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment. Mol Ther. 2022;30(10):3133–3154. doi: 10.1016/j.ymthe.2022.01.046.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zhang Y, Zhang Y, Jia Z, Zhang Z, Yang J. Cancer derived exosomes induce macrophages immunosuppressive polarization to promote bladder cancer progression. Cell Commun Signal. 2021;19(1):93. doi: 10.1186/s12964-021-00768-1.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang K, Zhi Y, Wu Y, Chen B, Bai J, Wang X. Tumor-derived exosomal miR-19b-3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via hippo pathway. Clin Transl Med. 2021;11(9):e478. doi: 10.1002/ctm2.478.
   PubMed Web of Science ®Google Scholar
• Zhao S, Mi Y, Guan B, Zheng B, Wei P, Gu Y, Zhang Z, Cai S, Xu Y, Li X, et al. Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer. J Hematol Oncol. 2020;13(1):156. doi: 10.1186/s13045-020-00991-2.
   PubMed Web of Science ®Google Scholar
• Chen Q, Li Y, Gao W, Chen L, Xu W, Zhu X. Exosome-mediated crosstalk between tumor and tumor-associated macrophages. Front Mol Biosci. 2021;8:764222. doi: 10.3389/fmolb.2021.764222.
   PubMed Web of Science ®Google Scholar
• Xiang X, Poliakov A, Liu C, Liu Y, Deng Z-B, Wang J, Cheng Z, Shah SV, Wang G-J, Zhang L, et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer. 2009;124(11):2621–2633. doi: 10.1002/ijc.24249.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xiang X, Zhuang X, Zhang S, Liu C, Cheng Z, Michalek S, Grizzle W, Zhang HG. Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am J Pathol. 2010;176(5):2490–2499. doi: 10.2353/ajpath.2010.090777.
   PubMed Web of Science ®Google Scholar
• Qiu W, Guo X, Li B, Wang J, Qi Y, Chen Z, Zhao R, Deng L, Qian M, Wang S, et al. Exosomal miR-1246 from glioma patient body fluids drives the differentiation and activation of myeloid-derived suppressor cells. Mol Ther. 2021;29(12):3449–3464. doi: 10.1016/j.ymthe.2021.06.023.
   PubMed Web of Science ®Google Scholar
• Guo X, Qiu W, Wang J, Liu Q, Qian M, Wang S, Zhang Z, Gao X, Chen Z, Guo Q, et al. Glioma exosomes mediate the expansion and function of myeloid-derived suppressor cells through microRNA-29a/Hbp1 and microRNA-92a/Prkar1a pathways. Int J Cancer. 2019;144(12):3111–3126. doi: 10.1002/ijc.32052.
   PubMed Web of Science ®Google Scholar
• Shokati E, Safari E. The immunomodulatory role of exosomal microRNA networks in the crosstalk between tumor-associated myeloid-derived suppressor cells and tumor cells. Int Immunopharmacol. 2023;120:110267. doi: 10.1016/j.intimp.2023.110267.
   PubMed Web of Science ®Google Scholar
• Ma F, Vayalil J, Lee G, Wang Y, Peng G. Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment. J Immunother Cancer. 2021;9(10):e003217. doi: 10.1136/jitc-2021-003217.
   PubMed Web of Science ®Google Scholar
• Rong L, Li R, Li S, Luo R. Immunosuppression of breast cancer cells mediated by transforming growth factor-β in exosomes from cancer cells. Oncol Lett. 2016;11(1):500–504. doi: 10.3892/ol.2015.3841.
   PubMed Web of Science ®Google Scholar
• Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015;3:83–92. doi: 10.2147/HP.S93413.
   PubMed Web of Science ®Google Scholar
• Shen T, Huang Z, Shi C, Pu X, Xu X, Wu Z, Ding G, Cao L. Pancreatic cancer-derived exosomes induce apoptosis of T lymphocytes through the p38 MAPK-mediated endoplasmic reticulum stress. FASEB J. 2020;34(6):8442–8458. doi: 10.1096/fj.201902186R.
   PubMed Web of Science ®Google Scholar
• Salimu J, Webber J, Gurney M, Al-Taei S, Clayton A, Tabi Z. Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes. J Extracell Vesicles. 2017;6(1):1368823. doi: 10.1080/20013078.2017.1368823.
   PubMed Web of Science ®Google Scholar
• Tucci M, Mannavola F, Passarelli A, Stucci LS, Cives M, Silvestris F. Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. Oncotarget. 2018;9(29):20826–20837. doi: 10.18632/oncotarget.24846.
   PubMedGoogle Scholar
• Batista IA, Quintas ST, Melo SA. The interplay of exosomes and NK cells in cancer biology. Cancers Basel. 2021;13(3):473. doi: 10.3390/cancers13030473.
   PubMed Web of Science ®Google Scholar
• Zhao J, Schlößer HA, Wang Z, Qin J, Li J, Popp F, Popp MC, Alakus H, Chon S-H, Hansen HP, et al. Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. Cancers Basel. 2019;11(6):874. doi: 10.3390/cancers11060874.
   PubMed Web of Science ®Google Scholar
• Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y, Kappes JC, Barnes S, Kimberly RP, Grizzle WE, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol. 2006;176(3):1375–1385. doi: 10.4049/jimmunol.176.3.1375.
   PubMed Web of Science ®Google Scholar
• Hong CS, Sharma P, Yerneni SS, Simms P, Jackson EK, Whiteside TL, Boyiadzis M. Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia. Sci Rep. 2017;7(1):14684. doi: 10.1038/s41598-017-14661-w.
   PubMed Web of Science ®Google Scholar
• Zhu X, Qin X, Wang X, Wang Y, Cao W, Zhang J, Chen W, Zhu X, Qin X, Wang X, et al. Oral cancer cell‑derived exosomes modulate natural killer cell activity by regulating the receptors on these cells. Int J Mol Med. 2020;46(6):2115–2125. doi: 10.3892/ijmm.2020.4736.
   PubMed Web of Science ®Google Scholar
• Chen JH, Xiang JY, Ding GP, Cao LP. Cholangiocarcinoma-derived exosomes inhibit the antitumor activity of cytokine-induced killer cells by down-regulating the secretion of tumor necrosis factor-α and perforin. J Zhejiang Univ Sci B. 2016;17(7):537–544. doi: 10.1631/jzus.B1500266.
   PubMed Web of Science ®Google Scholar
• Mincheva-Nilsson L, Baranov V. Cancer exosomes and NKG2D receptor-ligand interactions: impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance. Semin Cancer Biol. 2014;28:24–30. doi: 10.1016/j.semcancer.2014.02.010.
   PubMed Web of Science ®Google Scholar
• Cao Y, Wang X, Jin T, Tian Y, Dai C, Widarma C, Song R, Xu F. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal Transduct Target Ther. 2020;5(1):250. doi: 10.1038/s41392-020-00348-8.
   PubMed Web of Science ®Google Scholar
• Malla RR, Shailender G, Kamal MA. Exosomes: critical mediators of tumour microenvironment reprogramming. Curr Med Chem. 2021;28(39):8182–8202. doi: 10.2174/0929867328666201217105529.
   PubMed Web of Science ®Google Scholar
• Zaoui K, Rajadurai CV, Duhamel S, Park M. Arf6 regulates RhoB subcellular localization to control cancer cell invasion. J Cell Biol. 2019;218(11):3812–3826. doi: 10.1083/jcb.201806111.
   PubMed Web of Science ®Google Scholar
• Morrissey SM, Zhang F, Ding C, Montoya-Durango DE, Hu X, Yang C, Wang Z, Yuan F, Fox M, Zhang H-G, et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 2021;33(10):2040–2058.e10. doi: 10.1016/j.cmet.2021.09.002.
   PubMed Web of Science ®Google Scholar
• Li X, Peng X, Zhang C, Bai X, Li Y, Chen G, Guo H, He W, Zhou X, Gou X, et al. Bladder cancer-derived small extracellular vesicles promote tumor angiogenesis by inducing HBP-related metabolic reprogramming and SerRS O-GlcNAcylation in endothelial cells. Adv Sci. 2022;9(30):e2202993. doi: 10.1002/advs.202202993.
   Web of Science ®Google Scholar
• Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringnér M, Mörgelin M, Bourseau-Guilmain E, Bengzon J, Belting M, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A. 2013;110(18):7312–7317. doi: 10.1073/pnas.1220998110.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang H, Yang H, Bai M, Ning T, Deng T, Liu R, Fan Q, Zhu K, Li J, et al. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer. Mol Oncol. 2020;14(3):539–555. doi: 10.1002/1878-0261.12629.
   PubMed Web of Science ®Google Scholar
• Faict S, Oudaert I, D’Auria L, Dehairs J, Maes K, Vlummens P, De Veirman K, De Bruyne E, Fostier K, Vande Broek I, et al. The transfer of sphingomyelinase contributes to drug resistance in multiple myeloma. Cancers Basel. 2019;11(12):1823. doi: 10.3390/cancers11121823.
   PubMed Web of Science ®Google Scholar
• Wei Y, Wang D, Jin F, Bian Z, Li L, Liang H, Li M, Shi L, Pan C, Zhu D, et al. Pyruvate kinase type M2 promotes tumour cell exosome release via phosphorylating synaptosome-associated protein 23. Nat Commun. 2017;8(1):14041. doi: 10.1038/ncomms14041.
   PubMedGoogle Scholar
• Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, Tao Y, He Z, Chen C, Jiang Y, et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther. 2020;5(1):145. doi: 10.1038/s41392-020-00261-0.
   PubMed Web of Science ®Google Scholar
• Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–1492. doi: 10.1093/annonc/mdw168.
   PubMed Web of Science ®Google Scholar
• Meng L, Cheng Y, Tong X, Gan S, Ding Y, Zhang Y, Wang C, Xu L, Zhu Y, Wu J, et al. Tumor oxygenation and hypoxia inducible Factor-1 functional inhibition via a reactive oxygen species responsive nanoplatform for enhancing radiation therapy and abscopal effects. Acs Nano. 2018;12(8):8308–8322. doi: 10.1021/acsnano.8b03590.
   PubMed Web of Science ®Google Scholar
• Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409–425. doi: 10.1038/nrc3958.
   PubMed Web of Science ®Google Scholar
• Zhang L, Du X, Li Q, Qian L, Chen J, Liu C, Yu Q, Gan Z. A multimodal therapeutic nanoplatform overcoming tumor hypoxia heterogeneity for improved tumor chemoradiotherapy. Adv Funct Mater. 2022;32(34):2204629. doi: 10.1002/adfm.202204629.
   Web of Science ®Google Scholar
• Xiao L, Chen B, Wang W, Tian T, Qian H, Li X, Yu Y. Multifunctional Au@AgBiS2 nanoparticles as high-efficiency radiosensitizers to induce pyroptosis for cancer radioimmunotherapy. Adv Sci (Weinh). 2023 Sep 8;10(30):e2302141. 10.1002/advs.202302141.
   PubMedGoogle Scholar
• Ma X, Yao M, Gao Y, Yue Y, Li Y, Zhang T, Nie G, Zhao X, Liang X. Functional immune cell-derived exosomes engineered for the trilogy of radiotherapy sensitization. Adv Sci. 2022;9(23):e2106031. doi: 10.1002/advs.202106031.
   Web of Science ®Google Scholar
• Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24(11):2482–2490. doi: 10.1158/1078-0432.CCR-17-3070.
   PubMed Web of Science ®Google Scholar
• Skwarski M, McGowan DR, Belcher E, Di Chiara F, Stavroulias D, McCole M, Derham JL, Chu K-Y, Teoh E, Chauhan J, et al. Mitochondrial inhibitor atovaquone increases tumor oxygenation and inhibits hypoxic gene expression in patients with non–small cell lung cancer. Clin Cancer Res. 2021;27(9):2459–2469. doi: 10.1158/1078-0432.CCR-20-4128.
   PubMed Web of Science ®Google Scholar
• Benej M, Hong X, Vibhute S, Scott S, Wu J, Graves E, Le Q-T, Koong AC, Giaccia AJ, Yu B, et al. Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proc Natl Acad Sci U S A. 2018;115(42):10756–10761. doi: 10.1073/pnas.1808945115.
   PubMed Web of Science ®Google Scholar
• Wu P, Zhou Q, Zhu H, Zhuang Y, Bao J. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-fluorouracil and perfluorocarbon. BMC Cancer. 2020;20(1):354. doi: 10.1186/s12885-020-06803-7.
   PubMed Web of Science ®Google Scholar
• Zou MZ, Liu WL, Li CX, Zheng D-W, Zeng J-Y, Gao F, Ye J-J, Zhang X-Z. A multifunctional biomimetic nanoplatform for relieving hypoxia to enhance chemotherapy and inhibit the PD-1/PD-L1 axis. Small. 2018;14(28):e1801120. doi: 10.1002/smll.201801120.
   PubMed Web of Science ®Google Scholar
• Zhong T, Gao N, Guan Y, Liu Z, Guan J. Co-delivery of bioengineered exosomes and oxygen for treating critical limb ischemia in diabetic mice. Acs Nano. 2023;17(24):25157–25174. doi: 10.1021/acsnano.3c08088.
   PubMed Web of Science ®Google Scholar
• Huang J, Yu P, Liao M, Dong X, Xu J, Ming J, Bin D, Wang Y, Zhang F, Xia Y, et al. 2023. A self-charging salt water battery for antitumor therapy. Sci Adv. 9(13):eadf3992. doi: 10.1126/sciadv.adf3992.
   PubMed Web of Science ®Google Scholar
• Zhang H, Shi C, Han F, Li M, Ma H, Sui R, Long S, Sun W, Du J, Fan J, et al. Precise gliomas therapy: hypoxia-activated prodrugs sensitized by nano-photosensitizers. Biomater. 2022;289:121770. doi: 10.1016/j.biomaterials.2022.121770.
   PubMed Web of Science ®Google Scholar
• Rini BI, Pal SK, Escudier BJ, Atkins MB, Hutson TE, Porta C, Verzoni E, Needle MN, McDermott DF. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020;21(1):95–104. doi: 10.1016/S1470-2045(19)30735-1.
   PubMed Web of Science ®Google Scholar
• Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539(7627):112–117. doi: 10.1038/nature19796.
   PubMed Web of Science ®Google Scholar
• Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan B, Oudard S, Else T, Maranchie JK, Welsh SJ, et al. Belzutifan for renal cell carcinoma in von Hippel–Lindau disease. N Engl J Med. 2021;385(22):2036–2046. doi: 10.1056/NEJMoa2103425.
   PubMed Web of Science ®Google Scholar
• Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):70. doi: 10.1038/s41392-023-01332-8.
   PubMed Web of Science ®Google Scholar
• Yuan X, Ruan W, Bobrow B, Carmeliet P, Eltzschig HK. Targeting hypoxia-inducible factors: therapeutic opportunities and challenges. Nat Rev Drug Discov. 2023 Dec 20;23(3):175–200. doi:10.1038/s41573-023-00848-6.
   PubMed Web of Science ®Google Scholar
• Dimik M, Abeysinghe P, Logan J, Mitchell M. The exosome: a review of current therapeutic roles and capabilities in human reproduction. Drug Deliv Transl Res. 2023;13(2):473–502. doi: 10.1007/s13346-022-01225-3.
   PubMed Web of Science ®Google Scholar
• Sulea T, Rohani N, Baardsnes J, Corbeil CR, Deprez C, Cepero-Donates Y, Robert A, Schrag JD, Parat M, Duchesne M, et al. Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironment. Mabs-austin. 2020;12(1):1682866. doi: 10.1080/19420862.2019.1682866.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lee AG, Nguyen AW, Maynard JA. An antibody Fc engineered for conditional antibody-dependent cellular cytotoxicity at the low tumor microenvironment pH. J Biol Chem. 2022;298(4):101798. doi: 10.1016/j.jbc.2022.101798.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu J, Chen W, Wang W, Yang F, Liu X, Sheng Y, Du K, He M, Lyu X, et al. A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety. J Hematol Oncol. 2023;16(1):2. doi: 10.1186/s13045-023-01399-4.
   PubMed Web of Science ®Google Scholar
• Su Z, Dong S, Chen Y, Huang T, Qin B, Yang Q, Jiang X, Zou C. Microfluidics-enabled nanovesicle delivers CD47/PD-L1 antibodies to enhance antitumor immunity and reduce immunotoxicity in lung adenocarcinoma. Adv Sci (Weinh). 2023;10(20):e2206213. doi: 10.1002/advs.202206213.
   PubMedGoogle Scholar
• Zhang W, He Q, Lopez B, Hu J, Kundu A, Andraza MC, Kerner AR, Schreiber GH, Shepard HM, Frost GI, et al. Abstract PO074: Logic-gating HER2 CAR-T to the tumor microenvironment mitigates on-target, off-tumor toxicity without compromising cytotoxicity against HER2-over-expressing tumors. Cancer Immunol Res. 2021;9(2_Supplement):PO074–PO074. doi: 10.1158/2326-6074.TUMIMM20-PO074.
   Web of Science ®Google Scholar
• Corbet C, Feron O. Tumour acidosis: from the passenger to the driver’s seat. Nat Rev Cancer. 2017;17(10):577–593. doi: 10.1038/nrc.2017.77.
   PubMed Web of Science ®Google Scholar
• Renner K, Bruss C, Schnell A, Koehl G, Becker HM, Fante M, Menevse A-N, Kauer N, Blazquez R, Hacker L, et al. Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy. Cell Rep. 2019;29(1):135–150.e9. doi: 10.1016/j.celrep.2019.08.068.
   PubMed Web of Science ®Google Scholar
• Cappellesso F, Orban MP, Shirgaonkar N, Berardi E, Serneels J, Neveu M-A, Di Molfetta D, Piccapane F, Caroppo R, Debellis L, et al. Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer. Nat Cancer. 2022;3(12):1464–1483. doi: 10.1038/s43018-022-00470-2.
   PubMedGoogle Scholar
• Yang X, Xu C, Zhang X, Li P, Sun F, Liu X, Wang X, Kwok RTK, Yang J, Lam JWY, et al. Development of sulfonamide‐functionalized charge‐reversal AIE photosensitizers for precise photodynamic therapy in the acidic tumor microenvironment. Adv Funct Mater. 2023;33(30):2300746. doi: 10.1002/adfm.202300746.
   Web of Science ®Google Scholar
• Botha H, Farah CS, Koo K, Cirillo N, McCullough M, Paolini R, Celentano A. The role of glucose transporters in oral squamous cell carcinoma. Biomolecules. 2021;11(8):1070. doi: 10.3390/biom11081070.
   PubMed Web of Science ®Google Scholar
• Cao J, Cui S, Li S, Du C, Tian J, Wan S, Qian Z, Gu Y, Chen WR, Wang G, et al. Targeted cancer therapy with a 2-deoxyglucose–based adriamycin complex. Cancer Res. 2013;73(4):1362–1373. doi: 10.1158/0008-5472.CAN-12-2072.
   PubMed Web of Science ®Google Scholar
• Sztandera K, Działak P, Marcinkowska M, Stańczyk M, Gorzkiewicz M, Janaszewska A, Klajnert-Maculewicz B. Sugar modification enhances cytotoxic activity of PAMAM-doxorubicin conjugate in glucose-deprived MCF-7 cells – possible role of GLUT1 transporter. Pharm Res. 2019;36(10):140. doi: 10.1007/s11095-019-2673-9.
   PubMed Web of Science ®Google Scholar
• Lin YS, Tungpradit R, Sinchaikul S, An FM, Liu DZ, Phutrakul S, Chen ST. Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters. J Med Chem. 2008;51(23):7428–7441. doi: 10.1021/jm8006257.
   PubMed Web of Science ®Google Scholar
• Liu P, Lu Y, Gao X, Liu R, Zhang-Negrerie D, Shi Y, Wang Y, Wang S, Gao Q. Highly water-soluble platinum(II) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties. Chem Commun (Camb). 2013;49(24):2421–2423. doi: 10.1039/c3cc38589b.
   PubMed Web of Science ®Google Scholar
• Wang H, Yang X, Zhao C, Wang PG, Wang X. Glucose-conjugated platinum(IV) complexes as tumor-targeting agents: design, synthesis and biological evaluation. Bioorg Med Chem. 2019;27(8):1639–1645. doi: 10.1016/j.bmc.2019.03.006.
   PubMed Web of Science ®Google Scholar
• Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, Reynolds GE, Chi J-T, Wu J, Solow-Cordero DE, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011;3(94):94ra70. doi: 10.1126/scitranslmed.3002394.
   PubMed Web of Science ®Google Scholar
• Adams DJ, Ito D, Rees MG, Seashore-Ludlow B, Puyang X, Ramos AH, Cheah JH, Clemons PA, Warmuth M, Zhu P, et al. NAMPT is the cellular target of STF-31-like small-molecule probes. ACS Chem Biol. 2014;9(10):2247–2254. doi: 10.1021/cb500347p.
   PubMed Web of Science ®Google Scholar
• Reckzeh ES, Karageorgis G, Schwalfenberg M, Ceballos J, Nowacki J, Stroet MCM, Binici A, Knauer L, Brand S, Choidas A, et al. Inhibition of glucose transporters and glutaminase synergistically impairs tumor cell growth. Cell Chem Biol. 2019;26(9):1214–1228.e25. doi: 10.1016/j.chembiol.2019.06.005.
   PubMed Web of Science ®Google Scholar
• Siebeneicher H, Cleve A, Rehwinkel H, Neuhaus R, Heisler I, Müller T, Bauser M, Buchmann B. Identification and optimization of the first highly selective GLUT1 inhibitor BAY-876. Chem Med. 2016;11(20):2261–2271. doi: 10.1002/cmdc.201600276.
   Google Scholar
• Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller W, Allen E, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24(2):213–228. doi: 10.1016/j.ccr.2013.06.014.
   PubMed Web of Science ®Google Scholar
• Ganapathy-Kanniappan S, Geschwind JFH, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, Cole RN, Syed LH, Rao PP, Ota S, et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res. 2009;29(12):4909–4918.
   PubMed Web of Science ®Google Scholar
• Lin H, Zeng J, Xie R, Schulz MJ, Tedesco R, Qu J, Erhard KF, Mack JF, Raha K, Rendina AR, et al. Discovery of a novel 2,6-disubstituted glucosamine series of potent and selective hexokinase 2 inhibitors. ACS Med Chem Lett. 2016;7(3):217–222. doi: 10.1021/acsmedchemlett.5b00214.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Puri S, Leland P, Puri A, Moudgil T, Fox BA, Puri RK, Joshi BH. Subcellular compartmentalization of PKM2 identifies anti-PKM2 therapy response in vitro and in vivo mouse model of human non-small-cell lung cancer. PLoS One. 2019;14(5):e0217131. doi: 10.1371/journal.pone.0217131.
   PubMed Web of Science ®Google Scholar
• Xie H, Hanai JI, Ren JG, Kats L, Burgess K, Bhargava P, Signoretti S, Billiard J, Duffy K, Grant A, et al. Targeting lactate dehydrogenase–a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metabol. 2014;19(5):795–809. doi: 10.1016/j.cmet.2014.03.003.
   PubMed Web of Science ®Google Scholar
• Rajeshkumar NV, Dutta P, Yabuuchi S, de Wilde RF, Martinez GV, Le A, Kamphorst JJ, Rabinowitz JD, Jain SK, Hidalgo M, et al. Therapeutic targeting of the Warburg effect in pancreatic cancer relies on an absence of p53 function. Cancer Res. 2015;75(16):3355–3364. doi: 10.1158/0008-5472.CAN-15-0108.
   PubMed Web of Science ®Google Scholar
• Zhang SL, He Y, Tam KY. Targeting cancer metabolism to develop human lactate dehydrogenase (hLDH)5 inhibitors. Drug Discov Today. 2018;23(7):1407–1415. doi: 10.1016/j.drudis.2018.05.014.
   PubMed Web of Science ®Google Scholar
• Billiard J, Dennison JB, Briand J, Annan RS, Chai D, Colón M, Dodson CS, Gilbert SA, Greshock J, Jing J, et al. Quinoline 3-sulfonamides inhibit lactate dehydrogenase a and reverse aerobic glycolysis in cancer cells. Cancer Metab. 2013;1(1):19. doi: 10.1186/2049-3002-1-19.
   PubMedGoogle Scholar
• Wang N, Jiang X, Zhang S, Zhu A, Yuan Y, Xu H, Lei J, Yan C. Structural basis of human monocarboxylate transporter 1 inhibition by anti-cancer drug candidates. Cell. 2021;184(2):370–383.e13. doi: 10.1016/j.cell.2020.11.043.
   PubMed Web of Science ®Google Scholar
• Guan X, Morris ME. In vitro and in vivo efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic acid in the murine 4T1 breast tumor model. Aaps J. 2020;22(4):84. doi: 10.1208/s12248-020-00466-9.
   PubMed Web of Science ®Google Scholar
• Edwards DN, Ngwa VM, Raybuck AL, Wang S, Hwang Y, Kim LC, Cho SH, Paik Y, Wang Q, Zhang S, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021;131(4):e140100. doi: 10.1172/JCI140100.
   PubMed Web of Science ®Google Scholar
• Jin H, Wang S, Zaal EA, Wang C, Wu H, Bosma A, Jochems F, Isima N, Jin G, Lieftink C, et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. Elife. 2020;9:e56749. doi: 10.7554/eLife.56749.
   PubMed Web of Science ®Google Scholar
• Najumudeen AK, Ceteci F, Fey SK, Hamm G, Steven RT, Hall H, Nikula CJ, Dexter A, Murta T, Race AM, et al. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nat Genet. 2021;53(1):16–26. doi: 10.1038/s41588-020-00753-3.
   PubMed Web of Science ®Google Scholar
• Nguyen Cao TG, Truong Hoang Q, Kang JH, Kang SJ, Ravichandran V, Rhee WJ, Lee M, Ko YT, Shim MS. Bioreducible exosomes encapsulating glycolysis inhibitors potentiate mitochondria-targeted sonodynamic cancer therapy via cancer-targeted drug release and cellular energy depletion. Biomater. 2023;301:122242. doi: 10.1016/j.biomaterials.2023.122242.
   PubMed Web of Science ®Google Scholar
• Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther. 2021;6(1):72. doi: 10.1038/s41392-020-00449-4.
   PubMed Web of Science ®Google Scholar
• Liu L, Li H, Wang J, Zhang J, Liang XJ, Guo W, Gu Z. Leveraging macrophages for cancer theranostics. Adv Drug Deliv Rev. 2022;183:114136. doi: 10.1016/j.addr.2022.114136.
   PubMed Web of Science ®Google Scholar
• Anfray A, Ummarino U, Andón A, Allavena A. Current strategies to target tumor-associated-macrophages to improve anti-tumor immune responses. Cells. 2019;9(1):46. doi: 10.3390/cells9010046.
   PubMed Web of Science ®Google Scholar
• Beltraminelli T, De Palma M. Biology and therapeutic targeting of tumour-associated macrophages. J Pathol. 2020;250(5):573–592. doi: 10.1002/path.5403.
   PubMed Web of Science ®Google Scholar
• Gomez-Roca CA, Italiano A, Le Tourneau C, Cassier PA, Toulmonde M, D’Angelo SP, Campone M, Weber KL, Loirat D, Cannarile MA, et al. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. Ann Oncol. 2019;30(8):1381–1392. doi: 10.1093/annonc/mdz163.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057–5069. doi: 10.1158/0008-5472.CAN-13-3723.
   PubMed Web of Science ®Google Scholar
• Pradel LP, Ooi CH, Romagnoli S, Cannarile MA, Sade H, Rüttinger D, Ries CH. Macrophage susceptibility to emactuzumab (RG7155) treatment. Mol Cancer Ther. 2016;15(12):3077–3086. doi: 10.1158/1535-7163.MCT-16-0157.
   PubMed Web of Science ®Google Scholar
• Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Müller C, Jegg A-M, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16(8):949–956. doi: 10.1016/S1470-2045(15)00132-1.
   PubMed Web of Science ®Google Scholar
• Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol. 2017;66(6):1300–1312. doi: 10.1016/j.jhep.2017.02.026.
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572. doi: 10.1038/nri.2017.49.
   PubMed Web of Science ®Google Scholar
• Schmall A, Al-Tamari HM, Herold S, Kampschulte M, Weigert A, Wietelmann A, Vipotnik N, Grimminger F, Seeger W, Pullamsetti SS, et al. Macrophage and cancer cell cross-talk via CCR2 and CX3CR1 is a fundamental mechanism driving lung cancer. Am J Respir Crit Care Med. 2015;191(4):437–447. doi: 10.1164/rccm.201406-1137OC.
   PubMed Web of Science ®Google Scholar
• Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, Bentires-Alj M. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014;515(7525):130–133. doi: 10.1038/nature13862.
   PubMed Web of Science ®Google Scholar
• Yoon J, Le XT, Kim J, Lee H, Nguyen NT, Lee WT, Lee ES, Oh KT, Choi H-G, Youn YS, et al. Macrophage-reprogramming upconverting nanoparticles for enhanced TAM-mediated antitumor therapy of hypoxic breast cancer. J Control Release. 2023;360:482–495. doi: 10.1016/j.jconrel.2023.07.009.
   PubMed Web of Science ®Google Scholar
• Huang L, Xu R, Li W, Lv L, Lin C, Yang X, Yao Y, Saw PE, Xu X. Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy. Acta Biomater. 2023;162:98–109. doi: 10.1016/j.actbio.2023.03.014.
   PubMed Web of Science ®Google Scholar
• Cassetta L, Kitamura T. Macrophage targeting: opening new possibilities for cancer immunotherapy. Immunol. 2018;155(3):285–293. doi: 10.1111/imm.12976.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhao D, Li H, Zhang W, Lin Q, Wang X, Zheng S, Zhang L, Li L, Hu S, et al. Blocking iASPP/Nrf2/M-CSF axis improves anti-cancer effect of chemotherapy-induced senescence by attenuating M2 polarization. Cell Death Disease. 2022;13(2):166. doi: 10.1038/s41419-022-04611-4.
   PubMed Web of Science ®Google Scholar
• Myers KV, Amend SR, Pienta KJ. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Mol Cancer. 2019;18(1):94. doi: 10.1186/s12943-019-1022-2.
   PubMed Web of Science ®Google Scholar
• De Cicco P, Ercolano G, Ianaro A. The new era of cancer immunotherapy: targeting Myeloid-Derived suppressor cells to overcome immune evasion. Front Immunol. 2020;11:1680. doi: 10.3389/fimmu.2020.01680.
   PubMed Web of Science ®Google Scholar
• Bronte V, Serafini P, Apolloni E, Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother. 2001;24(6):431–446. doi: 10.1097/00002371-200111000-00001.
   PubMed Web of Science ®Google Scholar
• Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS, Qian J, Hailemichael Y, Nurieva R, Dwyer KC, et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med. 2014;20(6):676–681. doi: 10.1038/nm.3560.
   PubMed Web of Science ®Google Scholar
• Dang Y, Rutnam ZJ, Dietsch G, Lu H, Yang Y, Hershberg R, Disis ML. TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cells. J Leukoc Biol. 2018;103(1):157–164. doi: 10.1002/JLB.5AB0217-070R.
   PubMed Web of Science ®Google Scholar
• Eriksson E, Wenthe J, Irenaeus S, Loskog A, Ullenhag G. Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. J Transl Med. 2016;14(1):282. doi: 10.1186/s12967-016-1037-z.
   PubMed Web of Science ®Google Scholar
• Kanterman J, Sade-Feldman M, Biton M, Ish-Shalom E, Lasry A, Goldshtein A, Hubert A, Baniyash M. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res. 2014;74(21):6022–6035. doi: 10.1158/0008-5472.CAN-14-0657.
   PubMed Web of Science ®Google Scholar
• Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66(1):157–167. doi: 10.1136/gutjnl-2015-310514.
   PubMed Web of Science ®Google Scholar
• Umansky V, Blattner C, Gebhardt C, Utikal J. CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. Cancer Immunol Immunother. 2017;66(8):1015–1023. doi: 10.1007/s00262-017-1988-9.
   PubMed Web of Science ®Google Scholar
• Blattner C, Fleming V, Weber R, Himmelhan B, Altevogt P, Gebhardt C, Schulze TJ, Razon H, Hawila E, Wildbaum G, et al. CCR5+ Myeloid-derived suppressor cells are enriched and activated in melanoma lesions. Cancer Res. 2018;78(1):157–167. doi: 10.1158/0008-5472.CAN-17-0348.
   PubMed Web of Science ®Google Scholar
• Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Rüttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5(1):53. doi: 10.1186/s40425-017-0257-y.
   PubMed Web of Science ®Google Scholar
• Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells. 2020;9(3):561. doi: 10.3390/cells9030561.
   PubMed Web of Science ®Google Scholar
• Lin S, Wang J, Wang L, Wen J, Guo Y, Qiao W, Zhou J, Xu G, Zhi F. Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC. 2017;Am J Cancer Res. 7(1):41–52.
   PubMed Web of Science ®Google Scholar
• Weed DT, Vella JL, Reis IM, De la Fuente AC, Gomez C, Sargi Z, Nazarian R, Califano J, Borrello I, Serafini P, et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21(1):39–48. doi: 10.1158/1078-0432.CCR-14-1711.
   PubMed Web of Science ®Google Scholar
• Hassel JC, Jiang H, Bender C, Winkler J, Sevko A, Shevchenko I, Halama N, Dimitrakopoulou-Strauss A, Haefeli WE, Jäger D, et al. Tadalafil has biologic activity in human melanoma. Results of a pilot trial with tadalafil in patients with metastatic melanoma (TaMe). Oncoimmunol. 2017;6(9):e1326440. doi: 10.1080/2162402X.2017.1326440.
   PubMed Web of Science ®Google Scholar
• Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL, Bouabe H, Scudamore CL, Hancox T, Maecker H, et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014;510(7505):407–411. doi: 10.1038/nature13444.
   PubMed Web of Science ®Google Scholar
• Christmas BJ, Rafie CI, Hopkins AC, Scott BA, Ma HS, Cruz KA, Woolman S, Armstrong TD, Connolly RM, Azad NA, et al. Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. Cancer Immunol Res. 2018;6(12):1561–1577. doi: 10.1158/2326-6066.CIR-18-0070.
   PubMed Web of Science ®Google Scholar
• Tcyganov E, Mastio J, Chen E, Gabrilovich DI. Plasticity of myeloid-derived suppressor cells in cancer. Curr Opin Immunol. 2018;51:76–82. doi: 10.1016/j.coi.2018.03.009.
   PubMed Web of Science ®Google Scholar
• Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013;62(5):909–918. doi: 10.1007/s00262-013-1396-8.
   PubMed Web of Science ®Google Scholar
• Lathers DMR, Clark JI, Achille NJ, Young MRI. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother. 2004;53(5):422–430. doi: 10.1007/s00262-003-0459-7.
   PubMed Web of Science ®Google Scholar
• Fultang L, Panetti S, Ng M, Collins P, Graef S, Rizkalla N, Booth S, Lenton R, Noyvert B, Shannon-Lowe C, et al. MDSC targeting with gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. EBioMedicine. 2019;47:235–246. doi: 10.1016/j.ebiom.2019.08.025.
   PubMed Web of Science ®Google Scholar
• Alshetaiwi H, Pervolarakis N, McIntyre LL, Ma D, Nguyen Q, Rath JA, Nee K, Hernandez G, Evans K, Torosian L, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020;5(44):eaay6017. doi: 10.1126/sciimmunol.aay6017.
   PubMed Web of Science ®Google Scholar
• Alissafi T, Hatzioannou A, Mintzas K, Barouni RM, Banos A, Sormendi S, Polyzos A, Xilouri M, Wielockx B, Gogas H, et al. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells. J Clin Invest. 2018;128(9):3840–3852. doi: 10.1172/JCI120888.
   PubMed Web of Science ®Google Scholar
• Boettcher M, McManus MT. Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR. Mol Cell. 2015;58(4):575–585. doi: 10.1016/j.molcel.2015.04.028.
   PubMed Web of Science ®Google Scholar
• Colombo M, Moita C, van Niel G, Kowal J, Vigneron J, Benaroch P, Manel N, Moita LF, Théry C, Raposo G, et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci. 2013;126(Pt 24):5553–5565. doi: 10.1242/jcs.128868.
   PubMed Web of Science ®Google Scholar
• Hoshino D, Kirkbride KC, Costello K, Clark ES, Sinha S, Grega-Larson N, Tyska MJ, Weaver AM. Exosome secretion is enhanced by invadopodia and drives invasive behavior. Cell Rep. 2013;5(5):1159–1168. doi: 10.1016/j.celrep.2013.10.050.
   PubMed Web of Science ®Google Scholar
• Ostenfeld MS, Jeppesen DK, Laurberg JR, Boysen AT, Bramsen JB, Primdal-Bengtson B, Hendrix A, Lamy P, Dagnaes-Hansen F, Rasmussen MH, et al. Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. Cancer Res. 2014;74(20):5758–5771. doi: 10.1158/0008-5472.CAN-13-3512.
   PubMed Web of Science ®Google Scholar
• Sinha S, Hoshino D, Hong NH, Kirkbride KC, Grega-Larson NE, Seiki M, Tyska MJ, Weaver AM. Cortactin promotes exosome secretion by controlling branched actin dynamics. J Cell Biol. 2016;214(2):197–213. doi: 10.1083/jcb.201601025.
   PubMed Web of Science ®Google Scholar
• Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, Montabana E, Lang UE, Fu Q, Fong L, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177(2):414–427.e13. doi: 10.1016/j.cell.2019.02.016.
   PubMed Web of Science ®Google Scholar
• Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, Ivarsson Y, Depoortere F, Coomans C, Vermeiren E, et al. Syndecan–syntenin–ALIX regulates the biogenesis of exosomes. Nat Cell Biol. 2012;14(7):677–685. doi: 10.1038/ncb2502.
   PubMed Web of Science ®Google Scholar
• Wei D, Zhan W, Gao Y, Huang L, Gong R, Wang W, Zhang R, Wu Y, Gao S, Kang T, et al. RAB31 marks and controls an ESCRT-independent exosome pathway. Cell Res. 2021;31(2):157–177. doi: 10.1038/s41422-020-00409-1.
   PubMed Web of Science ®Google Scholar
• Peak TC, Panigrahi GK, Praharaj PP, Su Y, Shi L, Chyr J, Rivera‐Chávez J, Flores‐Bocanegra L, Singh R, Vander Griend DJ, et al. Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer. Mol Carcinog. 2020;59(1):62–72. doi: 10.1002/mc.23129.
   PubMed Web of Science ®Google Scholar
• Ruiz-Martinez M, Navarro A, Marrades RM, Viñolas N, Santasusagna S, Muñoz C, Ramírez J, Molins L, Monzo M. YKT6 expression, exosome release, and survival in non-small cell lung cancer. Oncotarget. 2016;7(32):51515–51524. doi: 10.18632/oncotarget.9862.
   PubMedGoogle Scholar
• Chen M, Mao A, Xu M, Weng Q, Mao J, Ji J. CRISPR-Cas9 for cancer therapy: opportunities and challenges. Cancer Lett. 2019;447:48–55. doi: 10.1016/j.canlet.2019.01.017.
   PubMed Web of Science ®Google Scholar
• Vakulskas CA, Behlke MA. 2019. Evaluation and reduction of CRISPR off-target cleavage events. Nucleic Acid Ther. 29(4):167–174. doi: 10.1089/nat.2019.0790.
   PubMed Web of Science ®Google Scholar
• Behr M, Zhou J, Xu B, Zhang H. 2021. In vivo delivery of CRISPR-Cas9 therapeutics: progress and challenges. Acta Pharm Sin B. 11(8):2150–2171. doi: 10.1016/j.apsb.2021.05.020.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li CW, Chan LC, Wei Y, Hsu J-M, Xia W, Cha J-H, Hou J, Hsu JL, Sun L, et al. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 2018;28(8):862–864. doi: 10.1038/s41422-018-0060-4.
   PubMed Web of Science ®Google Scholar
• Montermini L, Meehan B, Garnier D, Lee WJ, Lee TH, Guha A, Al-Nedawi K, Rak J. Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content. J Biol Chem. 2015;290(40):24534–24546. doi: 10.1074/jbc.M115.679217.
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Takahashi Y, Nishikawa M, Sano K, Morishita M, Charoenviriyakul C, Saji H, Takakura Y. Accelerated growth of B16BL6 tumor in mice through efficient uptake of their own exosomes by B16BL6 cells. Cancer Sci. 2017;108(9):1803–1810. doi: 10.1111/cas.13310.
   PubMed Web of Science ®Google Scholar
• Wang G, Xie L, Li B, Sang W, Yan J, Li J, Tian H, Li W, Zhang Z, Tian Y, et al. A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis. Nat Commun. 2021;12(1):5733. doi: 10.1038/s41467-021-25990-w.
   PubMed Web of Science ®Google Scholar
• Airola MV, Shanbhogue P, Shamseddine AA, Guja KE, Senkal CE, Maini R, Bartke N, Wu BX, Obeid LM, Garcia-Diaz M, et al. Structure of human nSmase2 reveals an interdomain allosteric activation mechanism for ceramide generation. Proc Natl Acad Sci U S A. 2017;114(28):E5549–E5558. doi: 10.1073/pnas.1705134114.
   PubMed Web of Science ®Google Scholar
• Tschuschke M, Kocherova I, Bryja A, Mozdziak P, Angelova Volponi A, Janowicz K, Sibiak R, Piotrowska-Kempisty H, Iżycki D, Bukowska D, et al. Inclusion biogenesis, methods of isolation and clinical application of human cellular exosomes. J Clin Med. 2020;9(2):436. doi: 10.3390/jcm9020436.
   PubMed Web of Science ®Google Scholar
• Yoo SW, Agarwal A, Smith MD, Khuder SS, Baxi EG, Thomas AG, Rojas C, Moniruzzaman M, Slusher BS, Bergles DE, et al. Inhibition of neutral sphingomyelinase 2 promotes remyelination. Sci Adv. 2020;6(40):eaba5210. doi: 10.1126/sciadv.aba5210.
   PubMed Web of Science ®Google Scholar
• Mullard A. First-in-class tissue factor-targeted antibody–drug conjugate secures FDA approval. Nat Rev Drug Discov. 2021;20(11):806–806. doi: 10.1038/d41573-021-00167-8.
   Web of Science ®Google Scholar
• Datta A, Kim H, Lal M, McGee L, Johnson A, Moustafa AA, Jones JC, Mondal D, Ferrer M, Abdel-Mageed AB, et al. Manumycin a suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells. Cancer Lett. 2017;408:73–81. doi: 10.1016/j.canlet.2017.08.020.
   PubMed Web of Science ®Google Scholar
• Datta A, Kim H, McGee L, Johnson AE, Talwar S, Marugan J, Southall N, Hu X, Lal M, Mondal D, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: a drug repurposing strategy for advanced cancer. Sci Rep. 2018;8(1):8161. doi: 10.1038/s41598-018-26411-7.
   PubMed Web of Science ®Google Scholar
• Sasabe E, Tomomura A, Liu H, Sento S, Kitamura N, Yamamoto T. Epidermal growth factor/epidermal growth factor receptor signaling blockage inhibits tumor cell-derived exosome uptake by oral squamous cell carcinoma through macropinocytosis. Cancer Sci. 2022;113(2):609–621. doi: 10.1111/cas.15225.
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Matrana MR, Tsang C, Atkinson B, Choueiri TK, Tannir NM. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. Hematol Oncol Clin North Am. 2011;25(4):853–869. doi: 10.1016/j.hoc.2011.05.003.
   PubMed Web of Science ®Google Scholar
• Greenberg JW, Kim H, Moustafa AA, Datta A, Barata PC, Boulares AH, Abdel-Mageed AB, Krane LS. Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma. Sci Rep. 2021;11(1):10200. doi: 10.1038/s41598-021-89655-w.
   PubMed Web of Science ®Google Scholar
• Wu X, Kang M, Wang D, Zhu M, Hu Y, Zhang Y, Deng C, Chen J, Teng L. Heparan sulfate analogues regulate tumor-derived exosome formation that attenuates exosome functions in tumor processes. Int J Biol Macromol. 2021;187:481–491. doi: 10.1016/j.ijbiomac.2021.07.110.
   PubMed Web of Science ®Google Scholar
• Shin JM, Lee CH, Son S, Kim CH, Lee JA, Ko H, Shin S, Song SH, Park S-S, Bae J-H, et al. Sulfisoxazole elicits robust antitumour immune response along with immune checkpoint therapy by inhibiting Exosomal PD-L1. Adv Sci. 2022;9(5):e2103245. doi: 10.1002/advs.202103245.
   Web of Science ®Google Scholar
• Im EJ, Lee CH, Moon PG, Rangaswamy GG, Lee B, Lee JM, Lee J-C, Jee J-G, Bae J-S, Kwon T-K, et al. Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor a. Nat Commun. 2019;10(1):1387. doi: 10.1038/s41467-019-09387-4.
   PubMed Web of Science ®Google Scholar
• Catalano M, O’Driscoll L. Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J Extracell Vesicles. 2020;9(1):1703244. doi: 10.1080/20013078.2019.1703244.
   PubMed Web of Science ®Google Scholar
• Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58. doi: 10.1038/nrd.2018.168.
   PubMed Web of Science ®Google Scholar
• Parvathaneni V, Kulkarni NS, Muth A, Gupta V. Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discov Today. 2019;24(10):2076–2085. doi: 10.1016/j.drudis.2019.06.014.
   PubMed Web of Science ®Google Scholar
• Orme JJ, Enninga EAL, Lucien-Matteoni F, Dale H, Burgstaler E, Harrington SM, Ball MK, Mansfield AS, Park SS, Block MS, et al. Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. J Immunother Cancer. 2020;8(2):e001113. doi: 10.1136/jitc-2020-001113.
   PubMed Web of Science ®Google Scholar
• Wu TH, Wu CH, Huang CJ, Chang YC. Anticlogging hemofiltration device for mass collection of circulating tumor cells by ligand-free size selection. Langmuir. 2021;37(11):3399–3409. doi: 10.1021/acs.langmuir.0c03613.
   PubMed Web of Science ®Google Scholar
• Tayebi M, Zhou Y, Tripathi P, Chandramohanadas R, Ai Y. Exosome purification and analysis using a facile microfluidic hydrodynamic trapping device. Anal Chem. 2020;92(15):10733–10742. doi: 10.1021/acs.analchem.0c02006.
   PubMed Web of Science ®Google Scholar
• Ma C, Wang S, Wang G, Wu Y, Yang T, Shen W, Zhuang Y, Zhang L, Liu X, Yang L, et al. Protein spectrum changes in exosomes after therapeutic plasma exchange in patients with neuromyelitis optica. J Clin Apher. 2020;35(3):206–216. doi: 10.1002/jca.21781.
   PubMed Web of Science ®Google Scholar
• Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495–499. doi: 10.1038/nature22396.
   PubMed Web of Science ®Google Scholar
• Lu T, Zhang Z, Zhang J, Pan X, Zhu X, Wang X, Li Z, Ruan M, Li H, Chen W, et al. CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment. J Extracell Vesicles. 2022;11(5):e12218. doi: 10.1002/jev2.12218.
   PubMed Web of Science ®Google Scholar